BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells

Blood

Volumn 114, Issue 7, 2009, Pages 1340-1343

  Ramirez, Pablo ^a   Rettig, Michael P ^a   Uy, Geoffrey L ^a   Deych, Elena ^a   Holt, Matthew S ^a   Ritchey, Julie K ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR; PROTEIN INHIBITOR; PROTEIN INHIBITOR BIO5192; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; 2 ((1 (3,5 DICHLOROBENZENESULFONYL)PYRROLIDINE 2 CARBONYL)AMINO) 4 (4 METHYL 2 (METHYL (2 (4 (3 O TOLYLUREIDO)PHENYL)ACETYL)AMINO)PENTANOYLAMINO)BUTYRIC ACID; 2-((1-(3,5-DICHLOROBENZENESULFONYL)PYRROLIDINE-2-CARBONYL)AMINO)-4-(4-METHYL-2-(METHYL-(2-(4-(3-O-TOLYLUREIDO)PHENYL)ACETYL)AMINO)PENTANOYLAMINO)BUTYRIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBANILAMIDE DERIVATIVE; CHEMOKINE RECEPTOR CXCR4; CXCL12 PROTEIN, MOUSE; CXCR4 PROTEIN, MOUSE; HETEROCYCLIC COMPOUND; OLIGOPEPTIDE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL POPULATION; CONTROLLED STUDY; ENGRAFTMENT; HEMATOPOIETIC STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLENECTOMY; STEM CELL MOBILIZATION; ANIMAL; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; METHODOLOGY;

ANIMALS; ANTI-HIV AGENTS; CHEMOKINE CXCL12; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; INTEGRIN ALPHA4BETA1; MICE; OLIGOPEPTIDES; PHENYLUREA COMPOUNDS; RECEPTORS, CXCR4;

EID: 70349348954     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-184721     Document Type: Article

References (16)

1. Kiel MJ, Radice GL, Morrison SJ. Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. Cell Stem Cell. 2007;1(2):204-217.
2. Xie T, Spradling AC. A niche maintaining germ line stem cells in the Drosophila ovary. Science. 2000;290(5490):328-330. (Pubitemid 30781412)
3. Kiger AA, White-Cooper H, Fuller MT. Somatic support cells restrict germline stem cell self-renewal and promote differentiation. Nature. 2000;407(6805):750-754. (Pubitemid 30780733)
4. Palis J. Ontogeny of erythropoiesis. Curr Opin Hematol. 2008;15(3):155-161.
5. Rose DM, Cardarelli PM, Cobb RR, Ginsberg MH. Soluble VCAM-1 binding to alpha4 integrins is cell-type specific and activation dependent and is disrupted during apoptosis in T cells. Blood. 2000;95(2):602-609.
6. Miller CL, Lai B. Human and mouse hematopoietic colony-forming cell assays. Methods Mol Biol. 2005;290:71-89.
7. Leone DR, Giza K, Gill A, et al. An assessment of the mechanistic differences between two integrin alpha 4 beta 1 inhibitors, the monoclonal antibody TA-2 and the small molecule BIO5192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2003;305(3):1150-1162. (Pubitemid 36617994)
8. Pepinsky RB, Lee WC, Cornebise M, et al. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin α4β1 with improved pharmaceutical properties. J Pharmacol Exp Ther. 2005;312(2):742-750. (Pubitemid 40189574)
9. Chigaev A, Waller A, Zwartz GJ, Buranda T, Sklar LA. Regulation of cell adhesion by affinity and conformational unbending of alpha4beta1 integrin. J Immunol. 2007;178(11):6828-6839.
10. Papayannopoulou T, Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA-4 integrin. Proc Natl Acad Sci U S A. 1993;90(20):9374-9378. (Pubitemid 23315786)
11. Bonig H, Wundes A, Chang KH, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111(7):3439-3441.
12. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA-4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 1997;90(12):4779- 4788. (Pubitemid 28007191)
13. Zohren F, Toutzaris D, Klarner V, Hartung HP, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood. 2008;111(7):3893-3895.
14. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant. 2008;41(4):331-338. (Pubitemid 351330727)
15. Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008;112(4):990-998.
16. Papayannopoulou T, Craddock C, Nakamoto B, Priestley GV, Wolf NS. The VLA-4/VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci U S A. 1995;92(21):9647-9651.